Fieke W Hoff, Suleyman Y Goksu, Naveen Premnath, Prapti A Patel, Ruth Ikpefan, Gurbakhash Kaur, Madhuri Vusirikala, Taha Bat, Weina Chen, Praveen Ramakrishnan Geethakumari, Larry D Anderson, Farrukh T Awan, Robert H Collins, Olga K Weinberg, Alagarraju Muthukumar, Stephen S Chung, Yazan F Madanat
{"title":"骨髓富集队列血液恶性肿瘤患者的SARS-CoV-2疫苗IgG抗体反应:单中心观察","authors":"Fieke W Hoff, Suleyman Y Goksu, Naveen Premnath, Prapti A Patel, Ruth Ikpefan, Gurbakhash Kaur, Madhuri Vusirikala, Taha Bat, Weina Chen, Praveen Ramakrishnan Geethakumari, Larry D Anderson, Farrukh T Awan, Robert H Collins, Olga K Weinberg, Alagarraju Muthukumar, Stephen S Chung, Yazan F Madanat","doi":"10.5644/ama2006-124.399","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>Patients diagnosed with hematologic malignancies are at increased risk for severe SARS-CoV-2 infection. We evaluated the serological IgG response following two doses of the SARS-CoV-2 vaccine in patients with hematologic malignancies.</p><p><strong>Methods: </strong>Patients treated at UT Southwestern Medical Center with a diagnosis of a myeloid or lymphoid neoplasm were included. SARS-CoV-2 vaccination response was defined as a positive quantifiable spike IgG antibody titer.</p><p><strong>Results: </strong>Sixty patients were included in the study and 60% were diagnosed with a myeloid neoplasm. The majority (85%) of the patients with a myeloid malignancy and 50% of the patients with a lymphoid malignancy mounted a serological response after receiving two doses of the vaccine.</p><p><strong>Conclusion: </strong>Vaccination should be offered irrespective of ongoing treatment or active disease. Findings require validation in a larger cohort of patients.</p>","PeriodicalId":38313,"journal":{"name":"Acta medica academica","volume":"52 1","pages":"30-36"},"PeriodicalIF":0.0000,"publicationDate":"2023-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/59/2b/AMA-52-30.PMC10316070.pdf","citationCount":"0","resultStr":"{\"title\":\"SARS-CoV-2 Vaccination IgG Antibody Responses in Patients with Hematologic Malignancies in a Myeloid Enriched Cohort: A Single Center Observation.\",\"authors\":\"Fieke W Hoff, Suleyman Y Goksu, Naveen Premnath, Prapti A Patel, Ruth Ikpefan, Gurbakhash Kaur, Madhuri Vusirikala, Taha Bat, Weina Chen, Praveen Ramakrishnan Geethakumari, Larry D Anderson, Farrukh T Awan, Robert H Collins, Olga K Weinberg, Alagarraju Muthukumar, Stephen S Chung, Yazan F Madanat\",\"doi\":\"10.5644/ama2006-124.399\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Objective: </strong>Patients diagnosed with hematologic malignancies are at increased risk for severe SARS-CoV-2 infection. We evaluated the serological IgG response following two doses of the SARS-CoV-2 vaccine in patients with hematologic malignancies.</p><p><strong>Methods: </strong>Patients treated at UT Southwestern Medical Center with a diagnosis of a myeloid or lymphoid neoplasm were included. SARS-CoV-2 vaccination response was defined as a positive quantifiable spike IgG antibody titer.</p><p><strong>Results: </strong>Sixty patients were included in the study and 60% were diagnosed with a myeloid neoplasm. The majority (85%) of the patients with a myeloid malignancy and 50% of the patients with a lymphoid malignancy mounted a serological response after receiving two doses of the vaccine.</p><p><strong>Conclusion: </strong>Vaccination should be offered irrespective of ongoing treatment or active disease. Findings require validation in a larger cohort of patients.</p>\",\"PeriodicalId\":38313,\"journal\":{\"name\":\"Acta medica academica\",\"volume\":\"52 1\",\"pages\":\"30-36\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-04-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/59/2b/AMA-52-30.PMC10316070.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Acta medica academica\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.5644/ama2006-124.399\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Acta medica academica","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5644/ama2006-124.399","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}
SARS-CoV-2 Vaccination IgG Antibody Responses in Patients with Hematologic Malignancies in a Myeloid Enriched Cohort: A Single Center Observation.
Objective: Patients diagnosed with hematologic malignancies are at increased risk for severe SARS-CoV-2 infection. We evaluated the serological IgG response following two doses of the SARS-CoV-2 vaccine in patients with hematologic malignancies.
Methods: Patients treated at UT Southwestern Medical Center with a diagnosis of a myeloid or lymphoid neoplasm were included. SARS-CoV-2 vaccination response was defined as a positive quantifiable spike IgG antibody titer.
Results: Sixty patients were included in the study and 60% were diagnosed with a myeloid neoplasm. The majority (85%) of the patients with a myeloid malignancy and 50% of the patients with a lymphoid malignancy mounted a serological response after receiving two doses of the vaccine.
Conclusion: Vaccination should be offered irrespective of ongoing treatment or active disease. Findings require validation in a larger cohort of patients.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
